IL303376A - מעכבי tead ושימושיהם - Google Patents

Info

Publication number

IL303376A

IL303376A IL303376A IL30337623A IL303376A IL 303376 A IL303376 A IL 303376A IL 303376 A IL303376 A IL 303376A IL 30337623 A IL30337623 A IL 30337623A IL 303376 A IL303376 A IL 303376A

Authority

IL

Israel

Prior art keywords

increased

cancer

compound

tead

pharmaceutically acceptable

Prior art date

2020-12-02

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title description 142
• 150000001875 compounds Chemical class 0.000 claims description 346
• 206010028980 Neoplasm Diseases 0.000 claims description 158
• 101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 claims description 115
• 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 claims description 112
• 201000011510 cancer Diseases 0.000 claims description 110
• 230000000694 effects Effects 0.000 claims description 101
• 230000004655 Hippo pathway Effects 0.000 claims description 90
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 83
• -1 substituted Chemical class 0.000 claims description 81
• 230000001965 increasing effect Effects 0.000 claims description 77
• 150000003839 salts Chemical class 0.000 claims description 71
• 101000597043 Homo sapiens Transcriptional enhancer factor TEF-5 Proteins 0.000 claims description 58
• 102100035147 Transcriptional enhancer factor TEF-5 Human genes 0.000 claims description 56
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 54
• 238000000034 method Methods 0.000 claims description 52
• 125000001931 aliphatic group Chemical group 0.000 claims description 50
• 230000002401 inhibitory effect Effects 0.000 claims description 49
• 101000597045 Homo sapiens Transcriptional enhancer factor TEF-3 Proteins 0.000 claims description 44
• 101000597035 Homo sapiens Transcriptional enhancer factor TEF-4 Proteins 0.000 claims description 44
• 230000014509 gene expression Effects 0.000 claims description 44
• 229920006395 saturated elastomer Polymers 0.000 claims description 43
• 102100035148 Transcriptional enhancer factor TEF-3 Human genes 0.000 claims description 42
• 102100035146 Transcriptional enhancer factor TEF-4 Human genes 0.000 claims description 42
• 201000010099 disease Diseases 0.000 claims description 42
• 229910052757 nitrogen Inorganic materials 0.000 claims description 42
• 208000035475 disorder Diseases 0.000 claims description 37
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 33
• 229910052717 sulfur Chemical group 0.000 claims description 33
• 239000011593 sulfur Chemical group 0.000 claims description 33
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 31
• 229910052760 oxygen Inorganic materials 0.000 claims description 31
• 239000001301 oxygen Chemical group 0.000 claims description 31
• 229910052736 halogen Inorganic materials 0.000 claims description 30
• 125000005842 heteroatom Chemical group 0.000 claims description 28
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 27
• 150000002367 halogens Chemical class 0.000 claims description 18
• 239000008194 pharmaceutical composition Substances 0.000 claims description 17
• 230000005764 inhibitory process Effects 0.000 claims description 15
• 230000002062 proliferating effect Effects 0.000 claims description 14
• 239000003981 vehicle Substances 0.000 claims description 9
• 230000001413 cellular effect Effects 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 8
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 8
• 239000002671 adjuvant Substances 0.000 claims description 7
• 230000009286 beneficial effect Effects 0.000 claims description 6
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
• 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
• 108700038175 YAP-Signaling Proteins Proteins 0.000 description 115
• 108090000623 proteins and genes Proteins 0.000 description 101
• 239000003814 drug Substances 0.000 description 100
• 239000000203 mixture Substances 0.000 description 79
• 230000003993 interaction Effects 0.000 description 62
• 230000026792 palmitoylation Effects 0.000 description 55
• 229940124597 therapeutic agent Drugs 0.000 description 52
• 235000002639 sodium chloride Nutrition 0.000 description 47
• 102000004169 proteins and genes Human genes 0.000 description 42
• 235000018102 proteins Nutrition 0.000 description 41
• 229940045207 immuno-oncology agent Drugs 0.000 description 36
• 239000002584 immunological anticancer agent Substances 0.000 description 36
• 238000011282 treatment Methods 0.000 description 31
• 229940121647 egfr inhibitor Drugs 0.000 description 30
• 239000005557 antagonist Substances 0.000 description 27
• 210000004027 cell Anatomy 0.000 description 27
• 230000008685 targeting Effects 0.000 description 27
• 230000007423 decrease Effects 0.000 description 24
• 230000003247 decreasing effect Effects 0.000 description 24
• 102000005962 receptors Human genes 0.000 description 22
• 108020003175 receptors Proteins 0.000 description 22
• 230000035772 mutation Effects 0.000 description 21
• 239000003795 chemical substances by application Substances 0.000 description 20
• 125000003118 aryl group Chemical group 0.000 description 19
• 230000027455 binding Effects 0.000 description 19
• 125000001424 substituent group Chemical group 0.000 description 19
• 206010009944 Colon cancer Diseases 0.000 description 18
• 125000000623 heterocyclic group Chemical group 0.000 description 18
• 206010033128 Ovarian cancer Diseases 0.000 description 16
• 208000029974 neurofibrosarcoma Diseases 0.000 description 15
• 102000001301 EGF receptor Human genes 0.000 description 14
• 108060006698 EGF receptor Proteins 0.000 description 14
• 108091000080 Phosphotransferase Proteins 0.000 description 14
• 239000002552 dosage form Substances 0.000 description 14
• 230000004077 genetic alteration Effects 0.000 description 14
• 231100000118 genetic alteration Toxicity 0.000 description 14
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 14
• 125000001072 heteroaryl group Chemical group 0.000 description 14
• 102000020233 phosphotransferase Human genes 0.000 description 14
• 206010061535 Ovarian neoplasm Diseases 0.000 description 13
• 125000002619 bicyclic group Chemical group 0.000 description 13
• 230000001225 therapeutic effect Effects 0.000 description 13
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 12
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 12
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
• 102000040945 Transcription factor Human genes 0.000 description 12
• 108091023040 Transcription factor Proteins 0.000 description 12
• 239000000556 agonist Substances 0.000 description 12
• 125000000217 alkyl group Chemical group 0.000 description 12
• 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 12
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 12
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
• 239000000523 sample Substances 0.000 description 11
• 238000002560 therapeutic procedure Methods 0.000 description 11
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
• 208000000172 Medulloblastoma Diseases 0.000 description 10
• 206010060862 Prostate cancer Diseases 0.000 description 10
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
• 230000003042 antagnostic effect Effects 0.000 description 10
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 10
• 201000002528 pancreatic cancer Diseases 0.000 description 10
• 208000008443 pancreatic carcinoma Diseases 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 10
• 208000026310 Breast neoplasm Diseases 0.000 description 9
• 206010018338 Glioma Diseases 0.000 description 9
• 102100037106 Merlin Human genes 0.000 description 9
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 9
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 9
• 108091006027 G proteins Proteins 0.000 description 8
• 102000034286 G proteins Human genes 0.000 description 8
• 208000032612 Glial tumor Diseases 0.000 description 8
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 8
• 125000004429 atom Chemical group 0.000 description 8
• 238000006731 degradation reaction Methods 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 208000005017 glioblastoma Diseases 0.000 description 8
• 150000002430 hydrocarbons Chemical group 0.000 description 8
• 201000001441 melanoma Diseases 0.000 description 8
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
• 229960003301 nivolumab Drugs 0.000 description 8
• 230000037361 pathway Effects 0.000 description 8
• 230000026731 phosphorylation Effects 0.000 description 8
• 238000006366 phosphorylation reaction Methods 0.000 description 8
• 102000016914 ras Proteins Human genes 0.000 description 8
• 230000002103 transcriptional effect Effects 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 7
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 7
• 108010074708 B7-H1 Antigen Proteins 0.000 description 7
• 206010006187 Breast cancer Diseases 0.000 description 7
• 101150015280 Cel gene Proteins 0.000 description 7
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 7
• 108091000058 GTP-Binding Proteins 0.000 description 7
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
• 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 7
• 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 7
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 102100027548 WW domain-containing transcription regulator protein 1 Human genes 0.000 description 7
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• 230000001028 anti-proliverative effect Effects 0.000 description 7
• 239000000427 antigen Substances 0.000 description 7
• 108091007433 antigens Proteins 0.000 description 7
• 102000036639 antigens Human genes 0.000 description 7
• 210000000988 bone and bone Anatomy 0.000 description 7
• 239000002775 capsule Substances 0.000 description 7
• 230000015556 catabolic process Effects 0.000 description 7
• 238000000576 coating method Methods 0.000 description 7
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 7
• 125000005843 halogen group Chemical group 0.000 description 7
• 150000002632 lipids Chemical class 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 229960003278 osimertinib Drugs 0.000 description 7
• DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical group COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 7
• 201000008968 osteosarcoma Diseases 0.000 description 7
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 230000001105 regulatory effect Effects 0.000 description 7
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 7
• 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 206010042863 synovial sarcoma Diseases 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 210000004881 tumor cell Anatomy 0.000 description 7
• 229910001868 water Inorganic materials 0.000 description 7
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
• 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 6
• 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 6
• 206010003571 Astrocytoma Diseases 0.000 description 6
• 229940123711 Bcl2 inhibitor Drugs 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 102000011068 Cdc42 Human genes 0.000 description 6
• 108050001278 Cdc42 Proteins 0.000 description 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 201000001342 Fallopian tube cancer Diseases 0.000 description 6
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 102000003964 Histone deacetylase Human genes 0.000 description 6
• 108090000353 Histone deacetylase Proteins 0.000 description 6
• 206010025323 Lymphomas Diseases 0.000 description 6
• 229940124647 MEK inhibitor Drugs 0.000 description 6
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 6
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 6
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 6
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 6
• 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 208000015634 Rectal Neoplasms Diseases 0.000 description 6
• 208000006265 Renal cell carcinoma Diseases 0.000 description 6
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 108700040558 Transcriptional Coactivator with PDZ-Binding Motif Proteins Proteins 0.000 description 6
• 230000001270 agonistic effect Effects 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 208000029742 colonic neoplasm Diseases 0.000 description 6
• 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 6
• 238000012217 deletion Methods 0.000 description 6
• 230000037430 deletion Effects 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 6
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 6
• 230000017945 hippo signaling cascade Effects 0.000 description 6
• 229940043355 kinase inhibitor Drugs 0.000 description 6
• 239000008101 lactose Substances 0.000 description 6
• 201000005202 lung cancer Diseases 0.000 description 6
• 208000020816 lung neoplasm Diseases 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 231100000252 nontoxic Toxicity 0.000 description 6
• 230000003000 nontoxic effect Effects 0.000 description 6
• 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 6
• 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 108010014186 ras Proteins Proteins 0.000 description 6
• 206010038038 rectal cancer Diseases 0.000 description 6
• 201000001275 rectum cancer Diseases 0.000 description 6
• 230000001603 reducing effect Effects 0.000 description 6
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 6
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
• 210000004872 soft tissue Anatomy 0.000 description 6
• 230000004936 stimulating effect Effects 0.000 description 6
• 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 6
• 108091006108 transcriptional coactivators Proteins 0.000 description 6
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 6
• 229960000237 vorinostat Drugs 0.000 description 6
• MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 5
• 102000004899 14-3-3 Proteins Human genes 0.000 description 5
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
• 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 5
• 239000012664 BCL-2-inhibitor Substances 0.000 description 5
• 101150013553 CD40 gene Proteins 0.000 description 5
• 229940045513 CTLA4 antagonist Drugs 0.000 description 5
• 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 5
• 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 5
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 5
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
• 206010027406 Mesothelioma Diseases 0.000 description 5
• 108091022875 Microtubule Proteins 0.000 description 5
• 102000029749 Microtubule Human genes 0.000 description 5
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
• 208000003019 Neurofibromatosis 1 Diseases 0.000 description 5
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 5
• 108091008606 PDGF receptors Proteins 0.000 description 5
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 5
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 5
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 5
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
• 229940079156 Proteasome inhibitor Drugs 0.000 description 5
• 108010016672 Syk Kinase Proteins 0.000 description 5
• 102100031873 Transcriptional coactivator YAP1 Human genes 0.000 description 5
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 5
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 5
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 5
• 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 229940100198 alkylating agent Drugs 0.000 description 5
• 239000002168 alkylating agent Substances 0.000 description 5
• 239000003886 aromatase inhibitor Substances 0.000 description 5
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 210000000805 cytoplasm Anatomy 0.000 description 5
• 239000002270 dispersing agent Substances 0.000 description 5
• 229960001433 erlotinib Drugs 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 229960002584 gefitinib Drugs 0.000 description 5
• 208000006359 hepatoblastoma Diseases 0.000 description 5
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 5
• 229910052739 hydrogen Inorganic materials 0.000 description 5
• 239000001257 hydrogen Substances 0.000 description 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
• 229960002411 imatinib Drugs 0.000 description 5
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 208000014018 liver neoplasm Diseases 0.000 description 5
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
• 210000004688 microtubule Anatomy 0.000 description 5
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 5
• 229950010895 midostaurin Drugs 0.000 description 5
• 125000002950 monocyclic group Chemical group 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 239000003207 proteasome inhibitor Substances 0.000 description 5
• 229960004641 rituximab Drugs 0.000 description 5
• 208000000587 small cell lung carcinoma Diseases 0.000 description 5
• 239000007909 solid dosage form Substances 0.000 description 5
• YJZSUCFGHXQWDM-UHFFFAOYSA-N 1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate Chemical compound OC1=CC=C(O)C(CNC=2C=CC(=CC=2)C(=O)OC23CC4CC(CC(C4)C2)C3)=C1 YJZSUCFGHXQWDM-UHFFFAOYSA-N 0.000 description 4
• AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 4
• 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 4
• XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 4
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
• 229940122815 Aromatase inhibitor Drugs 0.000 description 4
• 208000003174 Brain Neoplasms Diseases 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• 208000005243 Chondrosarcoma Diseases 0.000 description 4
• 208000009798 Craniopharyngioma Diseases 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 4
• 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 4
• 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 4
• 206010014967 Ependymoma Diseases 0.000 description 4
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
• 102100025334 Guanine nucleotide-binding protein G(q) subunit alpha Human genes 0.000 description 4
• 101710113864 Heat shock protein 90 Proteins 0.000 description 4
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 4
• 101000857888 Homo sapiens Guanine nucleotide-binding protein G(q) subunit alpha Proteins 0.000 description 4
• 101000775102 Homo sapiens Transcriptional coactivator YAP1 Proteins 0.000 description 4
• 208000008839 Kidney Neoplasms Diseases 0.000 description 4
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 4
• 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 4
• 241001465754 Metazoa Species 0.000 description 4
• 101710181812 Methionine aminopeptidase Proteins 0.000 description 4
• 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 4
• 102000004473 OX40 Ligand Human genes 0.000 description 4
• 108010042215 OX40 Ligand Proteins 0.000 description 4
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• 208000000453 Skin Neoplasms Diseases 0.000 description 4
• 206010041067 Small cell lung cancer Diseases 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 230000006044 T cell activation Effects 0.000 description 4
• 108091008874 T cell receptors Proteins 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 4
• 208000024313 Testicular Neoplasms Diseases 0.000 description 4
• 206010057644 Testis cancer Diseases 0.000 description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
• 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 4
• 201000005969 Uveal melanoma Diseases 0.000 description 4
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 4
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 4
• 229960001686 afatinib Drugs 0.000 description 4
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 4
• 125000003275 alpha amino acid group Chemical group 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 229960000397 bevacizumab Drugs 0.000 description 4
• ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical group OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 4
• 229940126587 biotherapeutics Drugs 0.000 description 4
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
• 229950004272 brigatinib Drugs 0.000 description 4
• 230000024245 cell differentiation Effects 0.000 description 4
• 230000004663 cell proliferation Effects 0.000 description 4
• 229960005395 cetuximab Drugs 0.000 description 4
• 229960002271 cobimetinib Drugs 0.000 description 4
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 description 4
• 125000000753 cycloalkyl group Chemical group 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 235000014113 dietary fatty acids Nutrition 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 229930195729 fatty acid Natural products 0.000 description 4
• 239000000194 fatty acid Substances 0.000 description 4
• 229960002949 fluorouracil Drugs 0.000 description 4
• 230000002496 gastric effect Effects 0.000 description 4
• 210000001035 gastrointestinal tract Anatomy 0.000 description 4
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 4
• IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical group C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 4
• 239000003701 inert diluent Substances 0.000 description 4
• 230000005865 ionizing radiation Effects 0.000 description 4
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 4
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• 229940124302 mTOR inhibitor Drugs 0.000 description 4
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 239000002609 medium Substances 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• 229960000513 necitumumab Drugs 0.000 description 4
• 229950008835 neratinib Drugs 0.000 description 4
• ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 4
• 239000000346 nonvolatile oil Substances 0.000 description 4
• 239000002777 nucleoside Substances 0.000 description 4
• 229960003347 obinutuzumab Drugs 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 229960001972 panitumumab Drugs 0.000 description 4
• 229960002621 pembrolizumab Drugs 0.000 description 4
• 235000021317 phosphate Nutrition 0.000 description 4
• LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
• 238000001959 radiotherapy Methods 0.000 description 4
• 125000006413 ring segment Chemical group 0.000 description 4
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 4
• OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 4
• 108010091666 romidepsin Proteins 0.000 description 4
• 201000000849 skin cancer Diseases 0.000 description 4
• 102000030938 small GTPase Human genes 0.000 description 4
• 108060007624 small GTPase Proteins 0.000 description 4
• 150000003384 small molecules Chemical class 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 4
• 201000003120 testicular cancer Diseases 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 4
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 4
• 229960001183 venetoclax Drugs 0.000 description 4
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 4
• 239000001993 wax Substances 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 4
• ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 3
• 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 3
• 108091006112 ATPases Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
• 102000009346 Adenosine receptors Human genes 0.000 description 3
• 108050000203 Adenosine receptors Proteins 0.000 description 3
• 102000043902 Angiomotin Human genes 0.000 description 3
• 108700020509 Angiomotin Proteins 0.000 description 3
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
• 229940122361 Bisphosphonate Drugs 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 208000006386 Bone Resorption Diseases 0.000 description 3
• 206010006143 Brain stem glioma Diseases 0.000 description 3
• 102100025221 CD70 antigen Human genes 0.000 description 3
• LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 3
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 208000017897 Carcinoma of esophagus Diseases 0.000 description 3
• 102000009410 Chemokine receptor Human genes 0.000 description 3
• 108050000299 Chemokine receptor Proteins 0.000 description 3
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
• 102400001368 Epidermal growth factor Human genes 0.000 description 3
• 101800003838 Epidermal growth factor Proteins 0.000 description 3
• 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 208000006168 Ewing Sarcoma Diseases 0.000 description 3
• OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 3
• 108010069236 Goserelin Proteins 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 3
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
• 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 3
• 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 3
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 3
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
• 102100034980 ICOS ligand Human genes 0.000 description 3
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 3
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 3
• 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 102000042838 JAK family Human genes 0.000 description 3
• 108091082332 JAK family Proteins 0.000 description 3
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 3
• 102000001419 Melatonin receptor Human genes 0.000 description 3
• 108050009605 Melatonin receptor Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 229940122255 Microtubule inhibitor Drugs 0.000 description 3
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 3
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 3
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 201000010133 Oligodendroglioma Diseases 0.000 description 3
• 239000012828 PI3K inhibitor Substances 0.000 description 3
• 229930012538 Paclitaxel Natural products 0.000 description 3
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
• 208000007641 Pinealoma Diseases 0.000 description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
• 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
• 206010038389 Renal cancer Diseases 0.000 description 3
• 201000000582 Retinoblastoma Diseases 0.000 description 3
• 102000042463 Rho family Human genes 0.000 description 3
• 108091078243 Rho family Proteins 0.000 description 3
• 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 3
• 108091007047 SCF complex Proteins 0.000 description 3
• 102000036366 SCF complex Human genes 0.000 description 3
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 3
• 206010061934 Salivary gland cancer Diseases 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 230000005867 T cell response Effects 0.000 description 3
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
• 229940123237 Taxane Drugs 0.000 description 3
• 108010017842 Telomerase Proteins 0.000 description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 description 3
• 102000004243 Tubulin Human genes 0.000 description 3
• 108090000704 Tubulin Proteins 0.000 description 3
• 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 3
• 102000014384 Type C Phospholipases Human genes 0.000 description 3
• 108010079194 Type C Phospholipases Proteins 0.000 description 3
• 102400000757 Ubiquitin Human genes 0.000 description 3
• 108090000848 Ubiquitin Proteins 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 3
• 241000700618 Vaccinia virus Species 0.000 description 3
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
• 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 3
• 208000014070 Vestibular schwannoma Diseases 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 208000004064 acoustic neuroma Diseases 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 235000010443 alginic acid Nutrition 0.000 description 3
• 229920000615 alginic acid Polymers 0.000 description 3
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000004450 alkenylene group Chemical group 0.000 description 3
• KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 230000001772 anti-angiogenic effect Effects 0.000 description 3
• 229940046836 anti-estrogen Drugs 0.000 description 3
• 230000001833 anti-estrogenic effect Effects 0.000 description 3
• 230000002927 anti-mitotic effect Effects 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 108010005774 beta-Galactosidase Proteins 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 150000004663 bisphosphonates Chemical class 0.000 description 3
• 230000024279 bone resorption Effects 0.000 description 3
• 229960001467 bortezomib Drugs 0.000 description 3
• 229940022399 cancer vaccine Drugs 0.000 description 3
• 238000009566 cancer vaccine Methods 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 229960004562 carboplatin Drugs 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• SZMJVTADHFNAIS-BJMVGYQFSA-N chidamide Chemical compound NC1=CC(F)=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)\C=C\C1=CC=CN=C1 SZMJVTADHFNAIS-BJMVGYQFSA-N 0.000 description 3
• 229950009221 chidamide Drugs 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
• 230000003436 cytoskeletal effect Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 3
• 229960003668 docetaxel Drugs 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 229950009791 durvalumab Drugs 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 3
• 229940116977 epidermal growth factor Drugs 0.000 description 3
• 229940011871 estrogen Drugs 0.000 description 3
• 239000000262 estrogen Substances 0.000 description 3
• 239000000328 estrogen antagonist Substances 0.000 description 3
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
• 229960005420 etoposide Drugs 0.000 description 3
• 229960000255 exemestane Drugs 0.000 description 3
• 150000004665 fatty acids Chemical class 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 201000010175 gallbladder cancer Diseases 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
• 102000054552 human TEAD1 Human genes 0.000 description 3
• 229960001507 ibrutinib Drugs 0.000 description 3
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
• 229960000908 idarubicin Drugs 0.000 description 3
• 229960003445 idelalisib Drugs 0.000 description 3
• 238000009169 immunotherapy Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 108091008042 inhibitory receptors Proteins 0.000 description 3
• 229960004768 irinotecan Drugs 0.000 description 3
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
• 201000010982 kidney cancer Diseases 0.000 description 3
• YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 3
• 229960004891 lapatinib Drugs 0.000 description 3
• 229960003881 letrozole Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 230000004777 loss-of-function mutation Effects 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 206010027191 meningioma Diseases 0.000 description 3
• 229960001428 mercaptopurine Drugs 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 230000001394 metastastic effect Effects 0.000 description 3
• 206010061289 metastatic neoplasm Diseases 0.000 description 3
• 231100000782 microtubule inhibitor Toxicity 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
• 229960001156 mitoxantrone Drugs 0.000 description 3
• RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 3
• 229950004847 navitoclax Drugs 0.000 description 3
• JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 3
• 208000007538 neurilemmoma Diseases 0.000 description 3
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 3
• 230000005937 nuclear translocation Effects 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 150000003833 nucleoside derivatives Chemical class 0.000 description 3
• 229960002450 ofatumumab Drugs 0.000 description 3
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
• 230000002246 oncogenic effect Effects 0.000 description 3
• 230000000174 oncolytic effect Effects 0.000 description 3
• 229960001756 oxaliplatin Drugs 0.000 description 3
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
• 229960001592 paclitaxel Drugs 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 239000000816 peptidomimetic Substances 0.000 description 3
• 229960002087 pertuzumab Drugs 0.000 description 3
• 235000019271 petrolatum Nutrition 0.000 description 3
• 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 3
• 229910052698 phosphorus Inorganic materials 0.000 description 3
• 239000011574 phosphorus Substances 0.000 description 3
• 208000024724 pineal body neoplasm Diseases 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 229950004043 radotinib Drugs 0.000 description 3
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
• 229960003452 romidepsin Drugs 0.000 description 3
• 206010039667 schwannoma Diseases 0.000 description 3
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
• 239000008247 solid mixture Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
• 229960004964 temozolomide Drugs 0.000 description 3
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
• 229960001278 teniposide Drugs 0.000 description 3
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 3
• 229960000303 topotecan Drugs 0.000 description 3
• 229960004066 trametinib Drugs 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 229960000575 trastuzumab Drugs 0.000 description 3
• 238000010798 ubiquitination Methods 0.000 description 3
• 230000034512 ubiquitination Effects 0.000 description 3
• 229960000241 vandetanib Drugs 0.000 description 3
• LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 3
• 229960004528 vincristine Drugs 0.000 description 3
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
• 230000003612 virological effect Effects 0.000 description 3
• 229960004276 zoledronic acid Drugs 0.000 description 3
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical group NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 2
• CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
• NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 description 2
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
• UMGQVUWXNOJOSJ-KMHUVPDISA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-[(1r)-1-phenylethyl]prop-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 UMGQVUWXNOJOSJ-KMHUVPDISA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 description 2
• 101710112812 14-3-3 protein Proteins 0.000 description 2
• PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 2
• RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 2
• QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
• BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
• BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 2
• 102000002627 4-1BB Ligand Human genes 0.000 description 2
• 108010082808 4-1BB Ligand Proteins 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• GUDJFFQZIISQJB-UHFFFAOYSA-N 4-cyano-5-(3,5-dichloropyridin-4-yl)sulfanyl-n-(4-methylsulfonylphenyl)thiophene-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1NC(=O)C(S1)=CC(C#N)=C1SC1=C(Cl)C=NC=C1Cl GUDJFFQZIISQJB-UHFFFAOYSA-N 0.000 description 2
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
• 102100040385 5-hydroxytryptamine receptor 4 Human genes 0.000 description 2
• 101710150225 5-hydroxytryptamine receptor 4 Proteins 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
• 101150056293 AJUBA gene Proteins 0.000 description 2
• 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• 108060003345 Adrenergic Receptor Proteins 0.000 description 2
• 102000017910 Adrenergic receptor Human genes 0.000 description 2
• OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 206010061424 Anal cancer Diseases 0.000 description 2
• 102100032187 Androgen receptor Human genes 0.000 description 2
• 102400000345 Angiotensin-2 Human genes 0.000 description 2
• 101800000733 Angiotensin-2 Proteins 0.000 description 2
• 208000007860 Anus Neoplasms Diseases 0.000 description 2
• 102000004452 Arginase Human genes 0.000 description 2
• 108700024123 Arginases Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
• CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• 229940121697 CD27 agonist Drugs 0.000 description 2
• 102100027207 CD27 antigen Human genes 0.000 description 2
• 102100038078 CD276 antigen Human genes 0.000 description 2
• 229940123189 CD40 agonist Drugs 0.000 description 2
• 229940122551 CD40 antagonist Drugs 0.000 description 2
• 108010001789 Calcitonin Receptors Proteins 0.000 description 2
• 102100038520 Calcitonin receptor Human genes 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 2
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
• 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• 201000009047 Chordoma Diseases 0.000 description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
• 208000027205 Congenital disease Diseases 0.000 description 2
• 108010074311 Corticotropin Receptors Proteins 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 102000005927 Cysteine Proteases Human genes 0.000 description 2
• 108010005843 Cysteine Proteases Proteins 0.000 description 2
• 230000006820 DNA synthesis Effects 0.000 description 2
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 2
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 102000015554 Dopamine receptor Human genes 0.000 description 2
• 108050004812 Dopamine receptor Proteins 0.000 description 2
• XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• 108010066805 F-Box Proteins Proteins 0.000 description 2
• 102000018700 F-Box Proteins Human genes 0.000 description 2
• 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 description 2
• 108091008794 FGF receptors Proteins 0.000 description 2
• 108010060374 FSH Receptors Proteins 0.000 description 2
• 102000008175 FSH Receptors Human genes 0.000 description 2
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
• 201000008808 Fibrosarcoma Diseases 0.000 description 2
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
• RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 244000060234 Gmelina philippensis Species 0.000 description 2
• 102400000932 Gonadoliberin-1 Human genes 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 101150112082 Gpnmb gene Proteins 0.000 description 2
• 108091006065 Gs proteins Proteins 0.000 description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
• 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000678419 Homo sapiens Adrenocorticotropic hormone receptor Proteins 0.000 description 2
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
• 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 2
• 101001072407 Homo sapiens Guanine nucleotide-binding protein subunit alpha-11 Proteins 0.000 description 2
• 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• 101000716693 Homo sapiens Sodium/iodide cotransporter Proteins 0.000 description 2
• 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
• 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
• 101000679907 Homo sapiens Tumor necrosis factor receptor superfamily member 27 Proteins 0.000 description 2
• 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 2
• 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 2
• 101001087426 Homo sapiens Tyrosine-protein phosphatase non-receptor type 14 Proteins 0.000 description 2
• 101000759994 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 47 Proteins 0.000 description 2
• 101000807859 Homo sapiens Vasopressin V2 receptor Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
• VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 2
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 2
• 229930186657 Lat Natural products 0.000 description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108091054455 MAP kinase family Proteins 0.000 description 2
• 102000043136 MAP kinase family Human genes 0.000 description 2
• MVBPAIHFZZKRGD-UHFFFAOYSA-N MTIC Chemical compound CNN=NC=1NC=NC=1C(N)=O MVBPAIHFZZKRGD-UHFFFAOYSA-N 0.000 description 2
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
• 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 2
• 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 description 2
• 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 206010067193 Naevus flammeus Diseases 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 239000005642 Oleic acid Substances 0.000 description 2
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
• 206010073338 Optic glioma Diseases 0.000 description 2
• SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 2
• 229940124060 PD-1 antagonist Drugs 0.000 description 2
• 229940123751 PD-L1 antagonist Drugs 0.000 description 2
• HZLFFNCLTRVYJG-WWGOJCOQSA-N Patidegib Chemical compound C([C@@]1(CC(C)=C2C3)O[C@@H]4C[C@H](C)CN[C@H]4[C@H]1C)C[C@H]2[C@H]1[C@H]3[C@@]2(C)CC[C@@H](NS(C)(=O)=O)C[C@H]2CC1 HZLFFNCLTRVYJG-WWGOJCOQSA-N 0.000 description 2
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
• 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
• 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
• 208000006787 Port-Wine Stain Diseases 0.000 description 2
• 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 2
• 108010050183 Prostaglandin Receptors Proteins 0.000 description 2
• 102000015433 Prostaglandin Receptors Human genes 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
• 102000014128 RANK Ligand Human genes 0.000 description 2
• 108010025832 RANK Ligand Proteins 0.000 description 2
• 102000000341 S-Phase Kinase-Associated Proteins Human genes 0.000 description 2
• 108010055623 S-Phase Kinase-Associated Proteins Proteins 0.000 description 2
• 108010040181 SF 1126 Proteins 0.000 description 2
• 101710204410 Scaffold protein Proteins 0.000 description 2
• 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
• 102000013380 Smoothened Receptor Human genes 0.000 description 2
• 108010090739 Smoothened Receptor Proteins 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• 108050001286 Somatostatin Receptor Proteins 0.000 description 2
• 102000011096 Somatostatin receptor Human genes 0.000 description 2
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• 102000003938 Thromboxane Receptors Human genes 0.000 description 2
• 108090000300 Thromboxane Receptors Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 2
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 2
• 102100040114 Trace amine-associated receptor 1 Human genes 0.000 description 2
• 108090000946 Trace amine-associated receptor 1 Proteins 0.000 description 2
• 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
• 102100022202 Tumor necrosis factor receptor superfamily member 27 Human genes 0.000 description 2
• 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 2
• 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 2
• 102100033015 Tyrosine-protein phosphatase non-receptor type 14 Human genes 0.000 description 2
• 102100025029 Ubiquitin carboxyl-terminal hydrolase 47 Human genes 0.000 description 2
• 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 2
• 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 2
• 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 description 2
• 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
• 102100037108 Vasopressin V2 receptor Human genes 0.000 description 2
• 241000711975 Vesicular stomatitis virus Species 0.000 description 2
• HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
• GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 102000035181 adaptor proteins Human genes 0.000 description 2
• 108091005764 adaptor proteins Proteins 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 108060000200 adenylate cyclase Proteins 0.000 description 2
• 102000030621 adenylate cyclase Human genes 0.000 description 2
• 210000002867 adherens junction Anatomy 0.000 description 2
• 229960004343 alendronic acid Drugs 0.000 description 2
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
• 229960003437 aminoglutethimide Drugs 0.000 description 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
• 229960002932 anastrozole Drugs 0.000 description 2
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
• 108010080146 androgen receptors Proteins 0.000 description 2
• 229950006323 angiotensin ii Drugs 0.000 description 2
• 230000002280 anti-androgenic effect Effects 0.000 description 2
• 230000006909 anti-apoptosis Effects 0.000 description 2
• 239000000051 antiandrogen Substances 0.000 description 2
• 239000002814 antineoplastic antimetabolite Substances 0.000 description 2
• 201000011165 anus cancer Diseases 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 229940126313 avutometinib Drugs 0.000 description 2
• 229960002756 azacitidine Drugs 0.000 description 2
• ZAXCMPAWRCMABN-UHFFFAOYSA-N azane;2-hydroxyacetic acid;platinum Chemical compound N.N.[Pt].OCC(O)=O ZAXCMPAWRCMABN-UHFFFAOYSA-N 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
• 229950003054 binimetinib Drugs 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 229960003008 blinatumomab Drugs 0.000 description 2
• 229960000455 brentuximab vedotin Drugs 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 229950003628 buparlisib Drugs 0.000 description 2
• BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 2
• 229960001573 cabazitaxel Drugs 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229960004117 capecitabine Drugs 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
• 108010021331 carfilzomib Proteins 0.000 description 2
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
• 229960002438 carfilzomib Drugs 0.000 description 2
• 239000012876 carrier material Substances 0.000 description 2
• 239000004359 castor oil Substances 0.000 description 2
• 229950006295 cerdulatinib Drugs 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• XDLYKKIQACFMJG-WKILWMFISA-N chembl1234354 Chemical compound C1=NC(OC)=CC=C1C(C1=O)=CC2=C(C)N=C(N)N=C2N1[C@@H]1CC[C@@H](OCCO)CC1 XDLYKKIQACFMJG-WKILWMFISA-N 0.000 description 2
• HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 229960002286 clodronic acid Drugs 0.000 description 2
• 230000003081 coactivator Effects 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 201000010989 colorectal carcinoma Diseases 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
• LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 2
• 229950002205 dacomitinib Drugs 0.000 description 2
• 229950006418 dactolisib Drugs 0.000 description 2
• JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960000975 daunorubicin Drugs 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 150000001982 diacylglycerols Chemical class 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
• 229940043264 dodecyl sulfate Drugs 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 230000001804 emulsifying effect Effects 0.000 description 2
• 239000002702 enteric coating Substances 0.000 description 2
• 238000009505 enteric coating Methods 0.000 description 2
• 229950006370 epacadostat Drugs 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• 229940082789 erbitux Drugs 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 102000015694 estrogen receptors Human genes 0.000 description 2
• 108010038795 estrogen receptors Proteins 0.000 description 2
• 229960003399 estrone Drugs 0.000 description 2
• 235000019441 ethanol Nutrition 0.000 description 2
• 229960005167 everolimus Drugs 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 229950011548 fadrozole Drugs 0.000 description 2
• 208000002026 familial multiple nevi flammei Diseases 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
• 229960000304 folic acid Drugs 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 239000011724 folic acid Substances 0.000 description 2
• 229960004421 formestane Drugs 0.000 description 2
• OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 229960002258 fulvestrant Drugs 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 229960001442 gonadorelin Drugs 0.000 description 2
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
• 229960002913 goserelin Drugs 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
• 201000002222 hemangioblastoma Diseases 0.000 description 2
• 125000004475 heteroaralkyl group Chemical group 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 102000055609 human TEAD2 Human genes 0.000 description 2
• 102000047205 human TEAD3 Human genes 0.000 description 2
• 102000056515 human TEAD4 Human genes 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 229960005236 ibandronic acid Drugs 0.000 description 2
• 229950007440 icotinib Drugs 0.000 description 2
• QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 239000000367 immunologic factor Substances 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 229950009034 indoximod Drugs 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 2
• 239000007972 injectable composition Substances 0.000 description 2
• 229940102223 injectable solution Drugs 0.000 description 2
• 229940102213 injectable suspension Drugs 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 229960005386 ipilimumab Drugs 0.000 description 2
• 229940084651 iressa Drugs 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 2
• MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 2
• 229940025735 jevtana Drugs 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 239000003202 long acting thyroid stimulator Substances 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 229950008001 matuzumab Drugs 0.000 description 2
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
• 229940083118 mekinist Drugs 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 2
• 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 description 2
• 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 239000004530 micro-emulsion Substances 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 229940071539 mirdametinib Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 229950010203 nimotuzumab Drugs 0.000 description 2
• 229950011068 niraparib Drugs 0.000 description 2
• 231100000344 non-irritating Toxicity 0.000 description 2
• 230000030648 nucleus localization Effects 0.000 description 2
• 229960000435 oblimersen Drugs 0.000 description 2
• MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 2
• 229950008516 olaratumab Drugs 0.000 description 2
• JLPDBLFIVFSOCC-XYXFTTADSA-N oleandrin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@H](CC[C@H]2[C@]3(C[C@@H]([C@@H]([C@@]3(C)CC[C@H]32)C=2COC(=O)C=2)OC(C)=O)O)[C@]3(C)CC1 JLPDBLFIVFSOCC-XYXFTTADSA-N 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 2
• 231100000590 oncogenic Toxicity 0.000 description 2
• 208000008511 optic nerve glioma Diseases 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 2
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
• 229960003978 pamidronic acid Drugs 0.000 description 2
• FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 2
• 229960005184 panobinostat Drugs 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 229960005547 pelareorep Drugs 0.000 description 2
• 229960005079 pemetrexed Drugs 0.000 description 2
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
• 238000002428 photodynamic therapy Methods 0.000 description 2
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
• 229950010773 pidilizumab Drugs 0.000 description 2
• 229950002592 pimasertib Drugs 0.000 description 2
• 201000004123 pineal gland cancer Diseases 0.000 description 2
• 229960004403 pixantrone Drugs 0.000 description 2
• 229910052697 platinum Inorganic materials 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
• 230000007319 proteasomal degradation pathway Effects 0.000 description 2
• 239000002718 pyrimidine nucleoside Substances 0.000 description 2
• DUPWHXBITIZIKZ-UHFFFAOYSA-N radotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3N=CC=NC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 DUPWHXBITIZIKZ-UHFFFAOYSA-N 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
• 229960002119 raloxifene hydrochloride Drugs 0.000 description 2
• 229960002633 ramucirumab Drugs 0.000 description 2
• 229940099538 rapamune Drugs 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 229950003687 ribociclib Drugs 0.000 description 2
• 102220094755 rs876660673 Human genes 0.000 description 2
• 229950004707 rucaparib Drugs 0.000 description 2
• 229960000215 ruxolitinib Drugs 0.000 description 2
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 2
• 229960005569 saridegib Drugs 0.000 description 2
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
• 229950010746 selumetinib Drugs 0.000 description 2
• 230000009919 sequestration Effects 0.000 description 2
• 230000007781 signaling event Effects 0.000 description 2
• 229910052710 silicon Inorganic materials 0.000 description 2
• 239000010703 silicon Substances 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 229960005325 sonidegib Drugs 0.000 description 2
• VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 2
• 229960003787 sorafenib Drugs 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 206010041823 squamous cell carcinoma Diseases 0.000 description 2
• HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• VDLGAZDAHPLOIR-VAZUXJHFSA-N sulanemadlin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@]2(C)CCCCCC\C=C\CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC5=CC=C(O)C=C5)NC(=O)[C@H](CCC(O)=O)NC2=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(N)=O VDLGAZDAHPLOIR-VAZUXJHFSA-N 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 229950001269 taselisib Drugs 0.000 description 2
• 239000003277 telomerase inhibitor Substances 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 229960003604 testosterone Drugs 0.000 description 2
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 2
• 201000002510 thyroid cancer Diseases 0.000 description 2
• 229960005324 tiludronic acid Drugs 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical group C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 2
• 229960001612 trastuzumab emtansine Drugs 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 229950007217 tremelimumab Drugs 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 229950011257 veliparib Drugs 0.000 description 2
• JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 2
• 229960003048 vinblastine Drugs 0.000 description 2
• 229960004982 vinblastine sulfate Drugs 0.000 description 2
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960002110 vincristine sulfate Drugs 0.000 description 2
• 229960004449 vismodegib Drugs 0.000 description 2
• BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
• 229910052727 yttrium Inorganic materials 0.000 description 2
• 229950008250 zalutumumab Drugs 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 description 1
• STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
• RNEACARJKXYVND-KQGZCTBQSA-N (2r)-2-[[(5z)-5-[(5-ethylfuran-2-yl)methylidene]-4-oxo-1,3-thiazol-2-yl]amino]-2-(4-fluorophenyl)acetic acid Chemical compound O1C(CC)=CC=C1\C=C/1C(=O)N=C(N[C@@H](C(O)=O)C=2C=CC(F)=CC=2)S\1 RNEACARJKXYVND-KQGZCTBQSA-N 0.000 description 1
• ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
• NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 1
• JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 description 1
• CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
• KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
• FDSDDLLOMXWXRY-JAQKLANPSA-N (3s)-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-3-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]-4-oxobutanoic acid;acetate Chemical compound CC([O-])=O.C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O)CCOCC1 FDSDDLLOMXWXRY-JAQKLANPSA-N 0.000 description 1
• SRSHBZRURUNOSM-DEOSSOPVSA-N (4-chlorophenyl) (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1[C@H]1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 SRSHBZRURUNOSM-DEOSSOPVSA-N 0.000 description 1
• DCGDPJCUIKLTDU-SUNYJGFJSA-N (4r)-4-[(1s)-1-fluoroethyl]-3-[2-[[(1s)-1-[4-methyl-5-[2-(trifluoromethyl)pyridin-4-yl]pyridin-2-yl]ethyl]amino]pyrimidin-4-yl]-1,3-oxazolidin-2-one Chemical compound C[C@H](F)[C@H]1COC(=O)N1C1=CC=NC(N[C@@H](C)C=2N=CC(=C(C)C=2)C=2C=C(N=CC=2)C(F)(F)F)=N1 DCGDPJCUIKLTDU-SUNYJGFJSA-N 0.000 description 1
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• GSQOBTOAOGXIFL-LFIBNONCSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-(3-phenylpropyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCC1=CC=CC=C1 GSQOBTOAOGXIFL-LFIBNONCSA-N 0.000 description 1
• GWCNJMUSWLTSCW-SFQUDFHCSA-N (e)-2-cyano-3-(3,4-dihydroxyphenyl)-n-(4-phenylbutyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCCCC1=CC=CC=C1 GWCNJMUSWLTSCW-SFQUDFHCSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• SOJJMSYMCLIQCZ-CYBMUJFWSA-N 1-[(2r)-4-[2-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-9-(2,2,2-trifluoroethyl)purin-8-yl]-2-methylpiperazin-1-yl]ethanone Chemical compound C1CN(C(C)=O)[C@H](C)CN1C1=NC2=C(N3CCOCC3)N=C(C=3C=NC(N)=NC=3)N=C2N1CC(F)(F)F SOJJMSYMCLIQCZ-CYBMUJFWSA-N 0.000 description 1
• SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 1
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
• WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical group C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
• YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
• VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
• VTJXFTPMFYAJJU-UHFFFAOYSA-N 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile Chemical compound OC1=CC=C(C=C(C#N)C#N)C=C1O VTJXFTPMFYAJJU-UHFFFAOYSA-N 0.000 description 1
• TXGKRVFSSHPBAJ-JKSUJKDBSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 TXGKRVFSSHPBAJ-JKSUJKDBSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
• BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
• LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
• RNMAUIMMNAHKQR-QFBILLFUSA-N 3-[2-[4-(trifluoromethoxy)anilino]-1-[(1R,5R)-3,3,5-trimethylcyclohexyl]benzimidazol-5-yl]propanoic acid Chemical compound FC(OC1=CC=C(C=C1)NC1=NC2=C(N1[C@H]1CC(C[C@H](C1)C)(C)C)C=CC(=C2)CCC(=O)O)(F)F RNMAUIMMNAHKQR-QFBILLFUSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
• PBJKWGWHZVXBGU-UHFFFAOYSA-N 3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol Chemical compound CC(C)C1=C(O)C(O)=CC2=C(O)C(C=3C(O)=C4C=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 PBJKWGWHZVXBGU-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
• ADGGYDAFIHSYFI-UHFFFAOYSA-N 5-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=NC(N2CCOCC2)=N1 ADGGYDAFIHSYFI-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
• PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-n-(5-methyl-1h-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
• PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
• PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 description 1
• JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
• HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
• 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 1
• 108091008803 APLNR Proteins 0.000 description 1
• 101150028385 ATG2 gene Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 description 1
• 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
• 208000009888 Adrenocortical Adenoma Diseases 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 229940097396 Aminopeptidase inhibitor Drugs 0.000 description 1
• YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
• 201000003076 Angiosarcoma Diseases 0.000 description 1
• 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
• 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
• 108090000644 Angiozyme Proteins 0.000 description 1
• 102100036822 Ankyrin repeat and KH domain-containing protein 1 Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 102000016555 Apelin receptors Human genes 0.000 description 1
• 235000003276 Apios tuberosa Nutrition 0.000 description 1
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
• 229940080328 Arginase inhibitor Drugs 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108010092778 Autophagy-Related Protein 7 Proteins 0.000 description 1
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
• 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
• 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 102100028519 B2 bradykinin receptor Human genes 0.000 description 1
• 101710085045 B2 bradykinin receptor Proteins 0.000 description 1
• 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
• QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
• 229940125565 BMS-986016 Drugs 0.000 description 1
• 229940124291 BTK inhibitor Drugs 0.000 description 1
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
• 229940122035 Bcl-XL inhibitor Drugs 0.000 description 1
• 206010060999 Benign neoplasm Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 108010073466 Bombesin Receptors Proteins 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 108091008927 CC chemokine receptors Proteins 0.000 description 1
• 102100031168 CCN family member 2 Human genes 0.000 description 1
• 101150042405 CCN1 gene Proteins 0.000 description 1
• 102000005674 CCR Receptors Human genes 0.000 description 1
• 108010046080 CD27 Ligand Proteins 0.000 description 1
• 101710185679 CD276 antigen Proteins 0.000 description 1
• 108010029697 CD40 Ligand Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 102100036008 CD48 antigen Human genes 0.000 description 1
• 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• 108010061299 CXCR4 Receptors Proteins 0.000 description 1
• 102000012000 CXCR4 Receptors Human genes 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
• 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
• 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
• 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 101100164184 Candida albicans (strain SC5314 / ATCC MYA-2876) SPO72 gene Proteins 0.000 description 1
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
• 108050007331 Cannabinoid receptor Proteins 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 101800001982 Cholecystokinin Proteins 0.000 description 1
• 102100025841 Cholecystokinin Human genes 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
• 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
• 241000242741 Cubozoa Species 0.000 description 1
• 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
• QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 102000000311 Cytosine Deaminase Human genes 0.000 description 1
• 108010080611 Cytosine Deaminase Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 230000004536 DNA copy number loss Effects 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
• 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 102000016680 Dioxygenases Human genes 0.000 description 1
• 108010028143 Dioxygenases Proteins 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
• 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
• CUDVHEFYRIWYQD-UHFFFAOYSA-N E-3810 free base Chemical compound C=1C=C2C(C(=O)NC)=CC=CC2=CC=1OC(C1=CC=2OC)=CC=NC1=CC=2OCC1(N)CC1 CUDVHEFYRIWYQD-UHFFFAOYSA-N 0.000 description 1
• 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 1
• 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
• 229940122558 EGFR antagonist Drugs 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
• 102100037354 Ectodysplasin-A Human genes 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
• 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
• 102000044591 ErbB-4 Receptor Human genes 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 1
• 101710109905 F-box/WD repeat-containing protein 1A Proteins 0.000 description 1
• 101150089023 FASLG gene Proteins 0.000 description 1
• 241000272186 Falco columbarius Species 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 108010076288 Formyl peptide receptors Proteins 0.000 description 1
• 102000011652 Formyl peptide receptors Human genes 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 101150037782 GAL2 gene Proteins 0.000 description 1
• WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
• 102000009596 GDP-dissociation inhibitor activity proteins Human genes 0.000 description 1
• 108040001987 GDP-dissociation inhibitor activity proteins Proteins 0.000 description 1
• 108010082772 GFB 111 Proteins 0.000 description 1
• 229940126656 GS-4224 Drugs 0.000 description 1
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
• 101710113436 GTPase KRas Proteins 0.000 description 1
• 102100039788 GTPase NRas Human genes 0.000 description 1
• 108091006109 GTPases Proteins 0.000 description 1
• 102000011392 Galanin receptor Human genes 0.000 description 1
• 108050001605 Galanin receptor Proteins 0.000 description 1
• 108010001498 Galectin 1 Proteins 0.000 description 1
• 102100021736 Galectin-1 Human genes 0.000 description 1
• 102100021735 Galectin-2 Human genes 0.000 description 1
• 102100031351 Galectin-9 Human genes 0.000 description 1
• 101710121810 Galectin-9 Proteins 0.000 description 1
• 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 108091006101 Gi proteins Proteins 0.000 description 1
• 102000034354 Gi proteins Human genes 0.000 description 1
• 108010063919 Glucagon Receptors Proteins 0.000 description 1
• 102100040890 Glucagon receptor Human genes 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 102000009127 Glutaminase Human genes 0.000 description 1
• 108010073324 Glutaminase Proteins 0.000 description 1
• 229940121727 Glutaminase inhibitor Drugs 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
• 108091006068 Gq proteins Proteins 0.000 description 1
• 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
• 102100034155 Guanine nucleotide-binding protein G(i) subunit alpha-1 Human genes 0.000 description 1
• 102100034154 Guanine nucleotide-binding protein G(i) subunit alpha-2 Human genes 0.000 description 1
• 102100034264 Guanine nucleotide-binding protein G(i) subunit alpha-3 Human genes 0.000 description 1
• 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 description 1
• 102100039261 Guanine nucleotide-binding protein G(t) subunit alpha-1 Human genes 0.000 description 1
• 102100039214 Guanine nucleotide-binding protein G(t) subunit alpha-2 Human genes 0.000 description 1
• 102100039215 Guanine nucleotide-binding protein G(t) subunit alpha-3 Human genes 0.000 description 1
• 102100039874 Guanine nucleotide-binding protein G(z) subunit alpha Human genes 0.000 description 1
• 102100036733 Guanine nucleotide-binding protein subunit alpha-12 Human genes 0.000 description 1
• 102100036703 Guanine nucleotide-binding protein subunit alpha-13 Human genes 0.000 description 1
• 102100023952 Guanine nucleotide-binding protein subunit alpha-14 Human genes 0.000 description 1
• 102100023954 Guanine nucleotide-binding protein subunit alpha-15 Human genes 0.000 description 1
• 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
• 238000004965 Hartree-Fock calculation Methods 0.000 description 1
• 102000003693 Hedgehog Proteins Human genes 0.000 description 1
• 108090000031 Hedgehog Proteins Proteins 0.000 description 1
• 208000001258 Hemangiosarcoma Diseases 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 102100024025 Heparanase Human genes 0.000 description 1
• 229940122588 Heparanase inhibitor Drugs 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
• 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
• 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
• 102000004384 Histamine H3 receptors Human genes 0.000 description 1
• 108090000981 Histamine H3 receptors Proteins 0.000 description 1
• 102000004187 Histamine H4 receptors Human genes 0.000 description 1
• 108090000796 Histamine H4 receptors Proteins 0.000 description 1
• 102000000543 Histamine Receptors Human genes 0.000 description 1
• 108010002059 Histamine Receptors Proteins 0.000 description 1
• 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 description 1
• 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
• 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 1
• 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 description 1
• 101000928335 Homo sapiens Ankyrin repeat and KH domain-containing protein 1 Proteins 0.000 description 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
• 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 1
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
• 101000880080 Homo sapiens Ectodysplasin-A Proteins 0.000 description 1
• 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 description 1
• 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
• 101001070526 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-1 Proteins 0.000 description 1
• 101001070508 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-2 Proteins 0.000 description 1
• 101000997034 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-3 Proteins 0.000 description 1
• 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
• 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
• 101000888178 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-1 Proteins 0.000 description 1
• 101000888142 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-2 Proteins 0.000 description 1
• 101000888145 Homo sapiens Guanine nucleotide-binding protein G(t) subunit alpha-3 Proteins 0.000 description 1
• 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
• 101001072398 Homo sapiens Guanine nucleotide-binding protein subunit alpha-12 Proteins 0.000 description 1
• 101001072481 Homo sapiens Guanine nucleotide-binding protein subunit alpha-13 Proteins 0.000 description 1
• 101000904077 Homo sapiens Guanine nucleotide-binding protein subunit alpha-14 Proteins 0.000 description 1
• 101000904080 Homo sapiens Guanine nucleotide-binding protein subunit alpha-15 Proteins 0.000 description 1
• 101100177268 Homo sapiens HCAR3 gene Proteins 0.000 description 1
• 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 description 1
• 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
• 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 description 1
• 101001039035 Homo sapiens Lutropin-choriogonadotropic hormone receptor Proteins 0.000 description 1
• 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 1
• 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 1
• 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
• 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
• 101000969581 Homo sapiens MOB kinase activator 1A Proteins 0.000 description 1
• 101001115744 Homo sapiens MOB kinase activator 1B Proteins 0.000 description 1
• 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 1
• 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
• 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
• 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 1
• 101000644718 Homo sapiens NEDD8-conjugating enzyme UBE2F Proteins 0.000 description 1
• 101000644669 Homo sapiens NEDD8-conjugating enzyme Ubc12 Proteins 0.000 description 1
• 101000978734 Homo sapiens Nephrocystin-3 Proteins 0.000 description 1
• 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
• 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
• 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 101000579300 Homo sapiens Prostaglandin F2-alpha receptor Proteins 0.000 description 1
• 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
• 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
• 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
• 101000693367 Homo sapiens SUMO-activating enzyme subunit 1 Proteins 0.000 description 1
• 101001094146 Homo sapiens SUMO-activating enzyme subunit 2 Proteins 0.000 description 1
• 101000939246 Homo sapiens SUMO-conjugating enzyme UBC9 Proteins 0.000 description 1
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 description 1
• 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
• 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
• 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 1
• 101000610609 Homo sapiens Tumor necrosis factor receptor superfamily member 10D Proteins 0.000 description 1
• 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
• 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 description 1
• 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 1
• 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 description 1
• 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 1
• 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
• 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
• 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 description 1
• 101000807344 Homo sapiens Ubiquitin-conjugating enzyme E2 A Proteins 0.000 description 1
• 101000807337 Homo sapiens Ubiquitin-conjugating enzyme E2 B Proteins 0.000 description 1
• 101000807354 Homo sapiens Ubiquitin-conjugating enzyme E2 C Proteins 0.000 description 1
• 101000772901 Homo sapiens Ubiquitin-conjugating enzyme E2 D2 Proteins 0.000 description 1
• 101000772913 Homo sapiens Ubiquitin-conjugating enzyme E2 D3 Proteins 0.000 description 1
• 101000644655 Homo sapiens Ubiquitin-conjugating enzyme E2 E1 Proteins 0.000 description 1
• 101000644653 Homo sapiens Ubiquitin-conjugating enzyme E2 E2 Proteins 0.000 description 1
• 101000644661 Homo sapiens Ubiquitin-conjugating enzyme E2 E3 Proteins 0.000 description 1
• 101000761646 Homo sapiens Ubiquitin-conjugating enzyme E2 G2 Proteins 0.000 description 1
• 101000644682 Homo sapiens Ubiquitin-conjugating enzyme E2 H Proteins 0.000 description 1
• 101000761725 Homo sapiens Ubiquitin-conjugating enzyme E2 J1 Proteins 0.000 description 1
• 101000761723 Homo sapiens Ubiquitin-conjugating enzyme E2 J2 Proteins 0.000 description 1
• 101000644689 Homo sapiens Ubiquitin-conjugating enzyme E2 K Proteins 0.000 description 1
• 101000761737 Homo sapiens Ubiquitin-conjugating enzyme E2 L3 Proteins 0.000 description 1
• 101000644684 Homo sapiens Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 1
• 101000761741 Homo sapiens Ubiquitin-conjugating enzyme E2 Q1 Proteins 0.000 description 1
• 101000808785 Homo sapiens Ubiquitin-conjugating enzyme E2 Q2 Proteins 0.000 description 1
• 101000808784 Homo sapiens Ubiquitin-conjugating enzyme E2 R1 Proteins 0.000 description 1
• 101000808789 Homo sapiens Ubiquitin-conjugating enzyme E2 R2 Proteins 0.000 description 1
• 101000837565 Homo sapiens Ubiquitin-conjugating enzyme E2 S Proteins 0.000 description 1
• 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 description 1
• 101000837580 Homo sapiens Ubiquitin-conjugating enzyme E2 U Proteins 0.000 description 1
• 101000772891 Homo sapiens Ubiquitin-conjugating enzyme E2 Z Proteins 0.000 description 1
• 101000808753 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 1 Proteins 0.000 description 1
• 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 1
• 101000809090 Homo sapiens Ubiquitin-fold modifier-conjugating enzyme 1 Proteins 0.000 description 1
• 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
• 101000662026 Homo sapiens Ubiquitin-like modifier-activating enzyme 7 Proteins 0.000 description 1
• 101000761740 Homo sapiens Ubiquitin/ISG15-conjugating enzyme E2 L6 Proteins 0.000 description 1
• 101000650162 Homo sapiens WW domain-containing transcription regulator protein 1 Proteins 0.000 description 1
• 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 description 1
• 102100039356 Hydroxycarboxylic acid receptor 3 Human genes 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 101710093458 ICOS ligand Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 102000010638 Kinesin Human genes 0.000 description 1
• 108010063296 Kinesin Proteins 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
• 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102100040788 Lutropin-choriogonadotropic hormone receptor Human genes 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 1
• 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 1
• 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
• 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
• 229940124761 MMP inhibitor Drugs 0.000 description 1
• 102100021437 MOB kinase activator 1A Human genes 0.000 description 1
• 102100024997 MOB kinase activator 1B Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
• 101710087603 Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
• 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
• 108090000950 Melanocortin Receptors Proteins 0.000 description 1
• 102000004378 Melanocortin Receptors Human genes 0.000 description 1
• 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
• 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
• 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
• YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
• 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 206010051676 Metastases to peritoneum Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
• 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 description 1
• 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
• FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
• RRMJMHOQSALEJJ-UHFFFAOYSA-N N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide Chemical compound CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 RRMJMHOQSALEJJ-UHFFFAOYSA-N 0.000 description 1
• PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 1
• CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
• 108091007791 NAE1 Proteins 0.000 description 1
• 102100029781 NEDD8-activating enzyme E1 regulatory subunit Human genes 0.000 description 1
• 102100020694 NEDD8-conjugating enzyme UBE2F Human genes 0.000 description 1
• 102100020710 NEDD8-conjugating enzyme Ubc12 Human genes 0.000 description 1
• GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 102100023188 Nephrocystin-3 Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 101100380548 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) apg-2 gene Proteins 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 108700010041 Nicotinic acid receptor Proteins 0.000 description 1
• 102100028646 Nociceptin receptor Human genes 0.000 description 1
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
• 108010064641 ONX 0912 Proteins 0.000 description 1
• YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
• 108010016076 Octreotide Proteins 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 102000003840 Opioid Receptors Human genes 0.000 description 1
• 108090000137 Opioid Receptors Proteins 0.000 description 1
• 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
• 108050008996 P2Y purinoceptor 1 Proteins 0.000 description 1
• 102100028045 P2Y purinoceptor 2 Human genes 0.000 description 1
• 101710096700 P2Y purinoceptor 2 Proteins 0.000 description 1
• 102100028070 P2Y purinoceptor 4 Human genes 0.000 description 1
• 108050009478 P2Y purinoceptor 4 Proteins 0.000 description 1
• 102100028074 P2Y purinoceptor 6 Human genes 0.000 description 1
• 101710096702 P2Y purinoceptor 6 Proteins 0.000 description 1
• 239000012661 PARP inhibitor Substances 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000012896 Peritoneal disease Diseases 0.000 description 1
• 101100237801 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) MLNS gene Proteins 0.000 description 1
• 102100030919 Phosphatidylcholine:ceramide cholinephosphotransferase 1 Human genes 0.000 description 1
• 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
• 102000017343 Phosphatidylinositol kinases Human genes 0.000 description 1
• 108050005377 Phosphatidylinositol kinases Proteins 0.000 description 1
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
• 201000005746 Pituitary adenoma Diseases 0.000 description 1
• 206010061538 Pituitary tumour benign Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102100035842 Prostaglandin E2 receptor EP1 subtype Human genes 0.000 description 1
• 101710097690 Prostaglandin E2 receptor EP1 subtype Proteins 0.000 description 1
• 102100024447 Prostaglandin E2 receptor EP3 subtype Human genes 0.000 description 1
• 101710125002 Prostaglandin E2 receptor EP3 subtype Proteins 0.000 description 1
• 102100028248 Prostaglandin F2-alpha receptor Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 102000002020 Protease-activated receptors Human genes 0.000 description 1
• 108050009310 Protease-activated receptors Proteins 0.000 description 1
• 102100022309 Protein KIBRA Human genes 0.000 description 1
• 101710145046 Protein kibra Proteins 0.000 description 1
• 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
• 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
• 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 1
• 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
• 102100022095 Protocadherin Fat 1 Human genes 0.000 description 1
• 101710095128 Protocadherin Fat 1 Proteins 0.000 description 1
• 102000000033 Purinergic Receptors Human genes 0.000 description 1
• 108010080192 Purinergic Receptors Proteins 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 102000018795 RELT Human genes 0.000 description 1
• 108010052562 RELT Proteins 0.000 description 1
• 101710178916 RING-box protein 1 Proteins 0.000 description 1
• 239000005464 Radotinib Substances 0.000 description 1
• 108091005682 Receptor kinases Proteins 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 229940123934 Reductase inhibitor Drugs 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 206010038934 Retinopathy proliferative Diseases 0.000 description 1
• 208000008938 Rhabdoid tumor Diseases 0.000 description 1
• 206010073334 Rhabdoid tumour Diseases 0.000 description 1
• 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
• 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 108060006706 SRC Proteins 0.000 description 1
• 102100025809 SUMO-activating enzyme subunit 1 Human genes 0.000 description 1
• 102100035250 SUMO-activating enzyme subunit 2 Human genes 0.000 description 1
• 102100029807 SUMO-conjugating enzyme UBC9 Human genes 0.000 description 1
• 102100028927 Secretin receptor Human genes 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
• 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
• 102100030403 Signal peptide peptidase-like 2A Human genes 0.000 description 1
• 108050005900 Signal peptide peptidase-like 2a Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 229940121856 Somatostatin receptor antagonist Drugs 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 1
• 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
• 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 1
• 101710155457 Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 1
• 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 description 1
• 101710155458 Sphingosine 1-phosphate receptor 4 Proteins 0.000 description 1
• 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
• 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 208000001662 Subependymal Glioma Diseases 0.000 description 1
• 108010002687 Survivin Proteins 0.000 description 1
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 108700040013 TEA Domain Transcription Factors Proteins 0.000 description 1
• 102000042834 TEC family Human genes 0.000 description 1
• 108091082333 TEC family Proteins 0.000 description 1
• 108091005735 TGF-beta receptors Proteins 0.000 description 1
• 101150082530 TJP1 gene Proteins 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• 102000016946 TWEAK Receptor Human genes 0.000 description 1
• 108010014401 TWEAK Receptor Proteins 0.000 description 1
• 108010072901 Tachykinin Receptors Proteins 0.000 description 1
• 102000007124 Tachykinin Receptors Human genes 0.000 description 1
• JXAGDPXECXQWBC-LJQANCHMSA-N Tanomastat Chemical compound C([C@H](C(=O)O)CC(=O)C=1C=CC(=CC=1)C=1C=CC(Cl)=CC=1)SC1=CC=CC=C1 JXAGDPXECXQWBC-LJQANCHMSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 229940123582 Telomerase inhibitor Drugs 0.000 description 1
• 108091033399 Telomestatin Proteins 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 229940122020 Thymidine phosphorylase inhibitor Drugs 0.000 description 1
• 229940122149 Thymidylate synthase inhibitor Drugs 0.000 description 1
• 102100029337 Thyrotropin receptor Human genes 0.000 description 1
• 239000004012 Tofacitinib Substances 0.000 description 1
• 102100025173 Trace amine-associated receptor 8 Human genes 0.000 description 1
• 101710116434 Trace amine-associated receptor 8 Proteins 0.000 description 1
• 101710193680 Transcriptional coactivator YAP1 Proteins 0.000 description 1
• 229940123468 Transferase inhibitor Drugs 0.000 description 1
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
• 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 1
• 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
• 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 description 1
• RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
• 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
• 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
• 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
• 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
• 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 1
• 102100040110 Tumor necrosis factor receptor superfamily member 10D Human genes 0.000 description 1
• 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
• 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 description 1
• 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 1
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
• 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
• 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 description 1
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
• 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
• 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
• 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 1
• 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 108010021430 Type 2 Melanocortin Receptor Proteins 0.000 description 1
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
• 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
• 108060008744 UBA3 Proteins 0.000 description 1
• 102000003436 UBA3 Human genes 0.000 description 1
• 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
• 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
• 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
• 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
• 101710132695 Ubiquitin-conjugating enzyme E2 Proteins 0.000 description 1
• 102100037261 Ubiquitin-conjugating enzyme E2 A Human genes 0.000 description 1
• 102100037262 Ubiquitin-conjugating enzyme E2 B Human genes 0.000 description 1
• 102100037256 Ubiquitin-conjugating enzyme E2 C Human genes 0.000 description 1
• 102100030439 Ubiquitin-conjugating enzyme E2 D2 Human genes 0.000 description 1
• 102100030425 Ubiquitin-conjugating enzyme E2 D3 Human genes 0.000 description 1
• 102100020711 Ubiquitin-conjugating enzyme E2 E1 Human genes 0.000 description 1
• 102100020704 Ubiquitin-conjugating enzyme E2 E2 Human genes 0.000 description 1
• 102100020709 Ubiquitin-conjugating enzyme E2 E3 Human genes 0.000 description 1
• 102100024870 Ubiquitin-conjugating enzyme E2 G2 Human genes 0.000 description 1
• 102100020698 Ubiquitin-conjugating enzyme E2 H Human genes 0.000 description 1
• 102100024860 Ubiquitin-conjugating enzyme E2 J1 Human genes 0.000 description 1
• 102100024863 Ubiquitin-conjugating enzyme E2 J2 Human genes 0.000 description 1
• 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 description 1
• 102100024861 Ubiquitin-conjugating enzyme E2 L3 Human genes 0.000 description 1
• 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 1
• 102100024846 Ubiquitin-conjugating enzyme E2 Q1 Human genes 0.000 description 1
• 102100038500 Ubiquitin-conjugating enzyme E2 Q2 Human genes 0.000 description 1
• 102100038466 Ubiquitin-conjugating enzyme E2 R1 Human genes 0.000 description 1
• 102100038499 Ubiquitin-conjugating enzyme E2 R2 Human genes 0.000 description 1
• 102100028718 Ubiquitin-conjugating enzyme E2 S Human genes 0.000 description 1
• 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 description 1
• 102100028710 Ubiquitin-conjugating enzyme E2 U Human genes 0.000 description 1
• 102100030441 Ubiquitin-conjugating enzyme E2 Z Human genes 0.000 description 1
• 102100038467 Ubiquitin-conjugating enzyme E2 variant 1 Human genes 0.000 description 1
• 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 1
• 102100038483 Ubiquitin-fold modifier-conjugating enzyme 1 Human genes 0.000 description 1
• 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
• 102100037938 Ubiquitin-like modifier-activating enzyme 7 Human genes 0.000 description 1
• 102100022979 Ubiquitin-like modifier-activating enzyme ATG7 Human genes 0.000 description 1
• 102100024843 Ubiquitin/ISG15-conjugating enzyme E2 L6 Human genes 0.000 description 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
• 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 description 1
• 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 description 1
• 101800003344 Vaccinia growth factor Proteins 0.000 description 1
• 201000003761 Vaginal carcinoma Diseases 0.000 description 1
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
• 102000004136 Vasopressin Receptors Human genes 0.000 description 1
• 108090000643 Vasopressin Receptors Proteins 0.000 description 1
• 108010004977 Vasopressins Proteins 0.000 description 1
• 102000002852 Vasopressins Human genes 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• MQTBAGAVFDZXKF-UHFFFAOYSA-N [2-fluoro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1F MQTBAGAVFDZXKF-UHFFFAOYSA-N 0.000 description 1
• 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
• 229950005186 abagovomab Drugs 0.000 description 1
• 108010023617 abarelix Proteins 0.000 description 1
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
• 229960002184 abarelix Drugs 0.000 description 1
• 229950001573 abemaciclib Drugs 0.000 description 1
• 229960000853 abiraterone Drugs 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
• 229950009084 adecatumumab Drugs 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 208000015234 adrenal cortex adenoma Diseases 0.000 description 1
• 201000003354 adrenal cortical adenoma Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 230000001780 adrenocortical effect Effects 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 229940042992 afinitor Drugs 0.000 description 1
• 108010081667 aflibercept Proteins 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229960001611 alectinib Drugs 0.000 description 1
• KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229940110282 alimta Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 125000004419 alkynylene group Chemical group 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 229950010482 alpelisib Drugs 0.000 description 1
• 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
• 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• 229950006061 anatumomab mafenatox Drugs 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 230000001548 androgenic effect Effects 0.000 description 1
• AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
• 229960005471 androstenedione Drugs 0.000 description 1
• AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
• 229960001232 anecortave Drugs 0.000 description 1
• 230000000964 angiostatic effect Effects 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 150000004056 anthraquinones Chemical class 0.000 description 1
• 238000011122 anti-angiogenic therapy Methods 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000719 anti-leukaemic effect Effects 0.000 description 1
• 230000001399 anti-metabolic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229950003145 apolizumab Drugs 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
• 229940078010 arimidex Drugs 0.000 description 1
• 229940087620 aromasin Drugs 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 229940014583 arranon Drugs 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
• 125000005228 aryl sulfonate group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229940102797 asparaginase erwinia chrysanthemi Drugs 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 229950004810 atamestane Drugs 0.000 description 1
• PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• 229950002916 avelumab Drugs 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 1
• XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
• 229950000971 baricitinib Drugs 0.000 description 1
• XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
• 229950001858 batimastat Drugs 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 229940077840 beleodaq Drugs 0.000 description 1
• 229960003094 belinostat Drugs 0.000 description 1
• 229960002707 bendamustine Drugs 0.000 description 1
• YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
• 229930195545 bengamide Natural products 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 201000007180 bile duct carcinoma Diseases 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008436 biogenesis Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 229940101815 blincyto Drugs 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 229940083476 bosulif Drugs 0.000 description 1
• 229960003736 bosutinib Drugs 0.000 description 1
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 229960005539 bryostatin 1 Drugs 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 229940056434 caprelsa Drugs 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 229960000419 catumaxomab Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000017455 cell-cell adhesion Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 1
• DSRNKUZOWRFQFO-UHFFFAOYSA-N cephalotaxine Natural products COC1=CC23CCCN2CCc4cc5OCOc5cc4C3=C1O DSRNKUZOWRFQFO-UHFFFAOYSA-N 0.000 description 1
• 229960001602 ceritinib Drugs 0.000 description 1
• VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• NNXDIGHYPZHXTR-ONEGZZNKSA-N chembl2035185 Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(O3)=CC=C3COC\C=C\COCC=2C=1OCCN1CCCC1 NNXDIGHYPZHXTR-ONEGZZNKSA-N 0.000 description 1
• PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
• ZGHQGWOETPXKLY-XVNBXDOJSA-N chembl77030 Chemical compound NC(=S)C(\C#N)=C\C1=CC=C(O)C(O)=C1 ZGHQGWOETPXKLY-XVNBXDOJSA-N 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 230000002113 chemopreventative effect Effects 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 229940107137 cholecystokinin Drugs 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• 229940103380 clolar Drugs 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229940034568 cometriq Drugs 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 229950002550 copanlisib Drugs 0.000 description 1
• PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
• 108091008034 costimulatory receptors Proteins 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 229960005061 crizotinib Drugs 0.000 description 1
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 229940109262 curcumin Drugs 0.000 description 1
• 239000004148 curcumin Substances 0.000 description 1
• 235000012754 curcumin Nutrition 0.000 description 1
• 208000030381 cutaneous melanoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 229940034075 cytarabine injection Drugs 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
• 229960002465 dabrafenib Drugs 0.000 description 1
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
• 229950007409 dacetuzumab Drugs 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 229960002204 daratumumab Drugs 0.000 description 1
• 229940094732 darzalex Drugs 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 229960003603 decitabine Drugs 0.000 description 1
• AUTFSFUMNFDPLH-KYMMNHPFSA-N degarelix acetate Chemical compound CC(O)=O.C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 AUTFSFUMNFDPLH-KYMMNHPFSA-N 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 230000001335 demethylating effect Effects 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 230000030609 dephosphorylation Effects 0.000 description 1
• 238000006209 dephosphorylation reaction Methods 0.000 description 1
• 229960003654 desoxycortone Drugs 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000009504 deubiquitination Effects 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 125000004431 deuterium atom Chemical group 0.000 description 1
• 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
• OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
• 229960004497 dinutuximab Drugs 0.000 description 1
• 125000000532 dioxanyl group Chemical group 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 229960002563 disulfiram Drugs 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 229940065910 docefrez Drugs 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229950005778 dovitinib Drugs 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000002183 duodenal effect Effects 0.000 description 1
• 229950004949 duvelisib Drugs 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 229950006700 edatrexate Drugs 0.000 description 1
• FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 229940073038 elspar Drugs 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• 229950002830 enadenotucirev Drugs 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 229950005837 entinostat Drugs 0.000 description 1
• 229960004671 enzalutamide Drugs 0.000 description 1
• WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
• 102000012803 ephrin Human genes 0.000 description 1
• 108060002566 ephrin Proteins 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
• 229950009760 epratuzumab Drugs 0.000 description 1
• QAMYWGZHLCQOOJ-WRNBYXCMSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-WRNBYXCMSA-N 0.000 description 1
• 229960000439 eribulin mesylate Drugs 0.000 description 1
• 229940014684 erivedge Drugs 0.000 description 1
• GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
• 229940051398 erwinaze Drugs 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 235000019439 ethyl acetate Nutrition 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 229960004945 etoricoxib Drugs 0.000 description 1
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
• 229940085363 evista Drugs 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000556 fingolimod Drugs 0.000 description 1
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
• 229940002006 firmagon Drugs 0.000 description 1
• XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
• 229960004413 flucytosine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 229940043075 fluocinolone Drugs 0.000 description 1
• FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 230000004907 flux Effects 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 125000003929 folic acid group Chemical group 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 229950008692 foretinib Drugs 0.000 description 1
• 229950005309 fostamatinib Drugs 0.000 description 1
• GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 229950004003 fresolimumab Drugs 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229940087158 gilotrif Drugs 0.000 description 1
• UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
• 229950009073 gimatecan Drugs 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 229950000918 glembatumumab Drugs 0.000 description 1
• 229940110231 gleostine Drugs 0.000 description 1
• 229940084910 gliadel Drugs 0.000 description 1
• 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229960003690 goserelin acetate Drugs 0.000 description 1
• 229940118951 halaven Drugs 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 108010037536 heparanase Proteins 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
• 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 230000037417 hyperactivation Effects 0.000 description 1
• 229940061301 ibrance Drugs 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 229940091204 imlygic Drugs 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000008629 immune suppression Effects 0.000 description 1
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
• 230000006028 immune-suppresssive effect Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 229960002993 ingenol mebutate Drugs 0.000 description 1
• 229940090044 injection Drugs 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229940005319 inlyta Drugs 0.000 description 1
• 229950004101 inotuzumab ozogamicin Drugs 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 229950007752 isatuximab Drugs 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 150000002537 isoquinolines Chemical class 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 229940011083 istodax Drugs 0.000 description 1
• 229960004130 itraconazole Drugs 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• 229960003648 ixazomib Drugs 0.000 description 1
• 229940111707 ixempra Drugs 0.000 description 1
• 229940045773 jakafi Drugs 0.000 description 1
• 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 229940000764 kyprolis Drugs 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 229950009640 lazertinib Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
• 229960003784 lenvatinib Drugs 0.000 description 1
• WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
• 229940064847 lenvima Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 229950002216 linifanib Drugs 0.000 description 1
• MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229950011263 lirilumab Drugs 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 238000012153 long-term therapy Methods 0.000 description 1
• 229940024740 lonsurf Drugs 0.000 description 1
• 229950008745 losoxantrone Drugs 0.000 description 1
• YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
• 208000022080 low-grade astrocytoma Diseases 0.000 description 1
• 229950004563 lucatumumab Drugs 0.000 description 1
• 229950004231 lucitanib Drugs 0.000 description 1
• 229960000994 lumiracoxib Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 229940100352 lynparza Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000031852 maintenance of location in cell Effects 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 229950002736 marizomib Drugs 0.000 description 1
• 229940034322 marqibo Drugs 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 229960003987 melatonin Drugs 0.000 description 1
• DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 229960005558 mertansine Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 201000004058 mixed glioma Diseases 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 229950007699 mogamulizumab Drugs 0.000 description 1
• 229950008814 momelotinib Drugs 0.000 description 1
• ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 108091006026 monomeric small GTPases Proteins 0.000 description 1
• VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 229950003968 motesanib Drugs 0.000 description 1
• RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
• BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
• JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
• UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 229950007221 nedaplatin Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
• 229960000801 nelarabine Drugs 0.000 description 1
• 229950010159 nemorubicin Drugs 0.000 description 1
• CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
• 210000005170 neoplastic cell Anatomy 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 229940080607 nexavar Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• 229940030115 ninlaro Drugs 0.000 description 1
• PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 1
• 150000002829 nitrogen Chemical class 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 108010020615 nociceptin receptor Proteins 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 230000037434 nonsense mutation Effects 0.000 description 1
• 230000030147 nuclear export Effects 0.000 description 1
• 230000025308 nuclear transport Effects 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 229950006584 obatoclax Drugs 0.000 description 1
• 229950009090 ocaratuzumab Drugs 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
• VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
• 229960000572 olaparib Drugs 0.000 description 1
• FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 1
• FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical group FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
• HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
• 230000004650 oncogenic pathway Effects 0.000 description 1
• 229940048191 onivyde Drugs 0.000 description 1
• 229950005750 oprozomib Drugs 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000000160 oxazolidinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 229950011410 pacritinib Drugs 0.000 description 1
• HWXVIOGONBBTBY-ONEGZZNKSA-N pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
• 229960004390 palbociclib Drugs 0.000 description 1
• 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 108700017947 pasireotide Proteins 0.000 description 1
• 229960005415 pasireotide Drugs 0.000 description 1
• NEEFMPSSNFRRNC-HQUONIRXSA-N pasireotide aspartate Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 NEEFMPSSNFRRNC-HQUONIRXSA-N 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
• 229950010632 perifosine Drugs 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 208000010918 peritoneal neoplasm Diseases 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 229950011309 pexastimogene devacirepvec Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 230000002165 photosensitisation Effects 0.000 description 1
• 239000003504 photosensitizing agent Substances 0.000 description 1
• 238000001126 phototherapy Methods 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000005545 phthalimidyl group Chemical group 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229940107670 picato Drugs 0.000 description 1
• IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
• 229950005566 picoplatin Drugs 0.000 description 1
• 229950004941 pictilisib Drugs 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 208000021310 pituitary gland adenoma Diseases 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• PEZPMAYDXJQYRV-UHFFFAOYSA-N pixantrone Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
• 230000010118 platelet activation Effects 0.000 description 1
• 229940063179 platinol Drugs 0.000 description 1
• 210000000557 podocyte Anatomy 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229960000688 pomalidomide Drugs 0.000 description 1
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
• 229940008606 pomalyst Drugs 0.000 description 1
• 229960001131 ponatinib Drugs 0.000 description 1
• PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
• 229960004293 porfimer sodium Drugs 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 229950003608 prinomastat Drugs 0.000 description 1
• YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
• 230000001686 pro-survival effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 102000017953 prostanoid receptors Human genes 0.000 description 1
• 108050007059 prostanoid receptors Proteins 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 239000000007 protein synthesis inhibitor Substances 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 230000004063 proteosomal degradation Effects 0.000 description 1
• 229940034080 provenge Drugs 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 125000001453 quaternary ammonium group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 229950001626 quizartinib Drugs 0.000 description 1
• CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000002534 radiation-sensitizing agent Substances 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
• 229930192524 radicicol Natural products 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 229950008933 refametinib Drugs 0.000 description 1
• 208000019465 refractory cytopenia of childhood Diseases 0.000 description 1
• 229960004836 regorafenib Drugs 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 229940120975 revlimid Drugs 0.000 description 1
• 229960000759 risedronic acid Drugs 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229950009213 rubitecan Drugs 0.000 description 1
• HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
• 229950008902 safingol Drugs 0.000 description 1
• NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
• NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
• 229950000106 samalizumab Drugs 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 108700027603 secretin receptor Proteins 0.000 description 1
• 229950003647 semaxanib Drugs 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 229960000714 sipuleucel-t Drugs 0.000 description 1
• 201000003708 skin melanoma Diseases 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
• DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 239000003206 sterilizing agent Substances 0.000 description 1
• 229940090374 stivarga Drugs 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 208000030819 subependymoma Diseases 0.000 description 1
• 239000001384 succinic acid Substances 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 229940034785 sutent Drugs 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 229940022873 synribo Drugs 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940081616 tafinlar Drugs 0.000 description 1
• 229950004550 talazoparib Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229950008461 talimogene laherparepvec Drugs 0.000 description 1
• 229950007866 tanespimycin Drugs 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 229940069905 tasigna Drugs 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• YVSQVYZBDXIXCC-INIZCTEOSA-N telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 description 1
• 229940061353 temodar Drugs 0.000 description 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 108040006218 thyroid-stimulating hormone receptor activity proteins Proteins 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
• QQHMKNYGKVVGCZ-UHFFFAOYSA-N tipiracil Chemical compound N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 QQHMKNYGKVVGCZ-UHFFFAOYSA-N 0.000 description 1
• 229960002952 tipiracil Drugs 0.000 description 1
• 230000009258 tissue cross reactivity Effects 0.000 description 1
• 229960000940 tivozanib Drugs 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 239000011731 tocotrienol Substances 0.000 description 1
• 229960001350 tofacitinib Drugs 0.000 description 1
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 229940100411 torisel Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 229960000977 trabectedin Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000003558 transferase inhibitor Substances 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 229940066958 treanda Drugs 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 229960003962 trifluridine Drugs 0.000 description 1
• VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
• 229950007127 trilaciclib Drugs 0.000 description 1
• 229960001670 trilostane Drugs 0.000 description 1
• KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 229940094060 tykerb Drugs 0.000 description 1
• TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 229940022919 unituxin Drugs 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229950005972 urelumab Drugs 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 229940050482 valchlor Drugs 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 229950001067 varlilumab Drugs 0.000 description 1
• 201000011531 vascular cancer Diseases 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 229960003726 vasopressin Drugs 0.000 description 1
• 229950000578 vatalanib Drugs 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• 229960003862 vemurafenib Drugs 0.000 description 1
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
• 230000028973 vesicle-mediated transport Effects 0.000 description 1
• 229940065658 vidaza Drugs 0.000 description 1
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229940028393 vincasar Drugs 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 208000012498 virus associated tumor Diseases 0.000 description 1
• 229960001771 vorozole Drugs 0.000 description 1
• XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
• 229940069559 votrient Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 208000013013 vulvar carcinoma Diseases 0.000 description 1
• 239000003871 white petrolatum Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 229940049068 xalkori Drugs 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 229940014556 xgeva Drugs 0.000 description 1
• 229940085728 xtandi Drugs 0.000 description 1
• 229940055760 yervoy Drugs 0.000 description 1
• 229940004212 yondelis Drugs 0.000 description 1
• 229940036061 zaltrap Drugs 0.000 description 1
• 229940034727 zelboraf Drugs 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 229960002760 ziv-aflibercept Drugs 0.000 description 1
• 229940061261 zolinza Drugs 0.000 description 1
• 229940002005 zometa Drugs 0.000 description 1
• 229950009819 zotarolimus Drugs 0.000 description 1
• CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
• 229940095188 zydelig Drugs 0.000 description 1
• 229940052129 zykadia Drugs 0.000 description 1
• 229940051084 zytiga Drugs 0.000 description 1